脊髄損傷マガジン tag:sekizui.info,2008:/news//2 2008-01-22T11:02:27Z 脊髄損傷関連の情報 Movable Type 3.35 ﾔﾊﾞｲまた(A;´･ω･)ｱｾｱｾ tag:sekizui.info,2008:/news//2.24 2008-01-22T10:56:50Z 2008-01-22T11:02:27Z また、このサイト更新するの忘れてた。 (A;´･ω･)ｱｾｱｾ さて作業始めると... また、このサイト更新するの忘れてた。 (A;´･ω･)ｱｾｱｾ さて作業始めるとするか・・ インド　Spinal cord injury treatment through Stem Cell therapy tag:sekizui.info,2008:/news//2.23 2008-01-11T13:12:32Z 2008-01-14T13:18:19Z http://www.hindu.com/thehindu/holnus/008... http://www.hindu.com/thehindu/holnus/008200801111921.htm Spinal cord injury treatment through Stem Cell therapy Coimbatore (PTI): After curing a heart patient through stem cell therapy, a city hospital has treated a 38-year old woman of spinal cord injuries using the same system. The woman had sustained a spinal cord injury, following a road accident, resulting in paralysis below the neck, without any movement in the limbs, Dr G Bhaktavasalam, Chairman, K G Hospital, told reporters here on Friday. After performing MRI, CT Scan and X-ray, she was diagnosed to have 'cervical cord injury' with a fracture of the neck bone, he said. Bone marrow stem cells were processed from the patient and were separated at Nichi-in Centre for Regenerative Medicine, Chennai and flown back to the hospital,he said. The surgery was performed yesterday and the woman recovering in the ICU, he said. The cervical cord was already exposed and the bone marrow stem cells were injected into the spinal cord and the neck bones were stabilised using metal plate screws. The cells taken from the patient had shown that there was no immunological rejection,he said. Hollywood Actor Christopher Reeve had same type of ailment in 1995 and if the stem cell transplantation treatment would have been available at that time, he could have been saved, Bhaktavatsalam claimed. ]]> リンク集を作り始める tag:sekizui.info,2008:/news//2.21 2008-01-11T11:43:19Z 2008-01-11T11:52:17Z とりあえず簡単にリンク集を作ってみた。 　↓コレ！ http://sekizui... http://sekizui.info/page/sekisontoha/link.html やっぱ長いこと調べてなかったから、どういうページがあるんだかサッパリ。 リンク集を作るためにインターネットを検索することで、自分も、どういうサイトがあるか覚えれるんじゃないかと。 良いサイトあったら教えてください。]]> メールマガジン再開しました！ tag:sekizui.info,2008:/news//2.20 2008-01-11T08:43:21Z 2008-01-11T08:51:12Z まぐまぐに、メールマガジンを復活してもらう手続きが完了しました！ これでもう登録... まぐまぐに、メールマガジンを復活してもらう手続きが完了しました！ これでもう登録解除が可能です。 登録できなくて困っていた方、解除できなくて困っていた方(笑)、もう出来ますのでやってください！ 。。。にしてもだ・・まだ書くこと決まってない。。。。 今月末までに発行しないと、また休止状態にするぞって、まぐまぐｻﾝからのメールに書いてあったので、なるべく早めに発行ｼﾏｽ♪ リンク集 tag:sekizui.info,2008:/news//2.19 2008-01-11T07:37:22Z 2008-01-11T07:41:34Z リンク集作成中・・ とりあえず 治療法研究、 ショップ、装具、 関連・・ とか、... リンク集作成中・・ とりあえず 治療法研究、 ショップ、装具、 関連・・ とか、かな？？？ 久々の更新 tag:sekizui.info,2008:/news//2.18 2008-01-10T06:34:46Z 2008-01-10T06:50:08Z 今日も更新してみたけど、やっぱこうやって見てみると手を加えないといけないところが... 今日も更新してみたけど、やっぱこうやって見てみると手を加えないといけないところがカナリある。汗 臨床試験実施状況のページなんてカナ古い情報になってると思うし・・ もう一度ネットを調べてみないと一体どうなっているのかサッパリわかんないよ。。 ま・無いよりはマシだと思って残しておくとするか。。。しかし早めに手を加えなければ！ 今はちょうど忙しい時期なんだよなあ・・・まだ半年分以上の帳簿の入力が終わってないし・・もうあと一ヶ月ぐらいしかない。。 il|li(´ω`;)il|liﾄﾞﾖ～ﾝ なんでも貯めてはダメだな・・・貯めては・・ (;´д`)=3ﾄﾎﾎ… お気軽にドゾ tag:sekizui.info,2008:/news//2.16 2008-01-10T05:49:47Z 2008-01-10T06:12:35Z 集まりや催し情報があったら教えてください。この「催し情報」のページで更新させてい... info@sekizui.info]]> Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury tag:sekizui.info,2008:/news//2.22 2008-01-09T13:03:24Z 2008-01-14T13:10:25Z http://ir.alseres.com/releasedetail.cfm?... http://ir.alseres.com/releasedetail.cfm?ReleaseID=284951 HOPKINTON, Mass., Jan 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc., (Nasdaq: ALSE), announced today that it has concluded enrollment in the Phase I/IIa clinical trial of Cethrin in acute spinal cord injury (SCI). A total of 48 subjects have been enrolled at 9 sites in the United States and Canada. We expect to release periodic updates of the data in 2008 following protocol-specified patient evaluations. "We continue to be encouraged by the safety and efficacy observations of the trial. The rate and magnitude of improvement of many subjects seems greater than the expected pattern of recovery," commented Dr. Mark Hurtt, Alseres Chief Medical Officer. "The findings of the Phase I/IIa study serve as a strong foundation for the acceleration of our development plans for Cethrin." Alseres intends to move forward with its previously announced plans for the placebo-controlled, Cethrin Phase IIb trial in acute spinal cord injury at sites in the U.S., Canada, Europe and other countries in 2008. "We believe that Cethrin continues to be the most advanced drug candidate in the clinic for the treatment of acute spinal cord injury in the world. If approved, Cethrin may offer hope for the nearly 11,000 new cases annually in the U.S. alone whose healthcare costs in the first year post-injury exceed $4 Billion," noted Dr. Mark Pykett, President and COO of Alseres. "We are pleased that the enrollment of the Phase I/IIa trial has concluded. Interim reported data have demonstrated encouraging safety and efficacy results over a 30-fold dose range. We look forward to the initiation of the Phase IIb trial in the first half of 2008." ]]> Cethrin contains a proprietary protein that inactivates the action of Rho, a key enzyme that prevents axon regeneration and recovery after SCI. It has been granted Orphan Drug Status in the U.S. In February 2005, enrollment began in an open-label, non-placebo-controlled, dose-escalating Phase I/IIa trial in subjects with acute SCI at sites in the United States and Canada. The trial assessed 5 dose levels of Cethrin from 0.3 mg to 9 mg in both thoracic and cervical injuries. The trial design includes a number of post-treatment evaluations of the subjects for safety and efficacy for up to one year after treatment. The efficacy measurements assess changes in subjects' sensory and motor functions, as well as overall recovery as measured by the American Spinal Injury Association, or ASIA, Impairment Scale. The ASIA Impairment Scale is used to score subjects within five categories from A to E, with A being complete impairment with no sensory or motor function below the site of injury and E being normal. Grades B through E designate increasing levels of motor and sensory function. The subjects in the Cethrin Phase I/IIa trial suffered a complete thoracic or cervical SCI and were thus classified as an A on the ASIA Impairment Scale at the time of enrollment in the trial. The 6-month interim data on 37 of these subjects treated with doses of up to 6 mg indicate that 27% of the Cethrin treated subjects improved from ASIA A to ASIA B or better. This is more than 400% greater than the conversion rate seen with the standard of care in a similarly designed study reported by Burns and colleagues in the Journal of Neurotrauma. When subjects with cervical injuries who were treated with Cethrin were analyzed separately, about 46% of the subjects exhibited a conversion rate from ASIA A to ASIA B or better. Moreover, about 18% of subjects overall and 38% of subjects with cervical injuries improved to ASIA C or better over the six months the hallmark of which is recovery of some motor function. In subjects with cervical injuries, the interim efficacy data also suggest that the response rate observed is dose-dependent at the doses up to 6 mg. To date, the safety and tolerability data for dose levels up to 6 mg indicate that Cethrin appears to be safe and well tolerated. There have been no serious adverse events related to Cethrin as determined by the investigators and the independent Data Safety Monitoring Board, or DSMB. There were two deaths of subjects enrolled in the trial. The DSMB and the clinical investigators attributed the two deaths to causes related to the subjects' initial Spinal Cord Injury, other injuries, or preexisting conditions and not related to Cethrin. About Alseres Pharmaceuticals, Inc. Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) is a biotechnology company engaged in developing breakthrough regenerative therapeutics to treat traumatic injuries and degenerative diseases. The Company maintains a world- class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE(R) which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston. Safe Harbor The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres Pharmaceuticals' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company's clinical development and trials for CETHRIN, the prospects of FDA approval of CETHRIN and the commercialization, including partnering opportunities, of CETHRIN. Forward- looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres Pharmaceuticals from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres Pharmaceuticals is providing the information in this press release as of this date and assumes no obligations to update the information in this press release. Contact: Sharon Correia Director, Corporate Communications scorreia@alseres.com 508-497-2360 ext. 224 SOURCE Alseres Pharmaceuticals, Inc. http://www.alseres.com Copyright (C) 2008 PR Newswire. All rights reserved 大統領選とips細胞 tag:sekizui.info,2008:/news//2.15 2008-01-09T10:47:09Z 2008-01-09T10:56:03Z http://sekizui.info/news/2008/01/post_8.... http://sekizui.info/news/2008/01/post_8.html おっクリストファーリーブに触れてる！ >>受精卵を使わない万能細胞が登場したためか、ＥＳ細胞論争に勢いはない。 言われて見れば、たしかに・・・・大統領選にも大きく影響するなんて、いかに大きな発見だったか改めて実感！ >>日本も今年は選挙の年になるだろう。その時には、世界の動向を左右するほどの、科学政策論争も聞かせてほしい。 そうなって欲しいけど、カナーーーーーーリ期待薄のような気がする(笑)]]> しかし。。よく消えなかったな(^^; tag:sekizui.info,2008:/news//2.14 2008-01-09T10:09:38Z 2008-01-09T10:31:22Z これだけページに手を加えてなかったのに、よく消えなかったなあ。。 消えるサイトと... がんばるぞ！・・・っていうつもり汗。運が良かったんだな。たぶん。ｱﾌﾞﾅｲｱﾌﾞﾅｲ ]]> 余録：米大統領選と科学　毎日新聞 tag:sekizui.info,2008:/news//2.13 2008-01-09T10:00:32Z 2008-01-09T10:03:19Z 毎日新聞　2008年1月9日　東京朝刊 http://mainichi.jp/s... http://mainichi.jp/select/opinion/yoroku/news/20080109ddm001070034000c.html 余録：「スーパーマン」を演じた米国の俳優クリストファー・リーブさんが… 　「スーパーマン」を演じた米国の俳優クリストファー・リーブさんが亡くなったのは前回の米大統領選の最中だった。９５年の落馬事故で脊髄（せきずい）を損傷し、車椅子で活動を続けていたが、力尽きた。直後に妻が民主党候補の応援演説に立った。ヒト胚（はい）性幹細胞（ＥＳ細胞）研究の必要性を訴えるためだ▲ＥＳ細胞は「元祖万能細胞」で、再生医療の切り札と目されてきた。ここから神経細胞を作って移植すれば脊髄損傷の治療にも役立つかもしれない。リーブさんも期待をかけ、「再び歩く」と宣言していた。一方で、受精卵を壊して作るため共和党のブッシュ大統領は否定的で、民主党との間で一大争点となっていた ]]> ▲今度の大統領選はどうか。米科学誌「サイエンス」の新年号は「科学と次期大統領」を特集している。受精卵を使わない万能細胞が登場したためか、ＥＳ細胞論争に勢いはない。代わりに注目されるのは温暖化対策だ▲民主党のクリントン候補は、２０５０年に二酸化炭素の排出を９０年比で８０％削減するため、再生可能エネルギーに資金を投じるという。オバマ候補はバイオ燃料や排出権取引に注目する。共和党のマケイン候補も、温暖化対策を最重要課題と位置づける▲誰が勝っても米国の温暖化対策が変わることは間違いないだろう。その時に世界がどう変化するか。日本も単に米国追随ではいられない▲温暖化以外でも各候補は基礎科学、宇宙開発、医学研究と、さまざまな発言をしている。その政策が時には世界に影響するから要注意だ。日本も今年は選挙の年になるだろう。その時には、世界の動向を左右するほどの、科学政策論争も聞かせてほしい。 中国関連AP通信Researchers ask: Is China the sleeping giant of biotech? tag:sekizui.info,2008:/news//2.12 2008-01-08T12:06:03Z 2008-01-08T12:08:41Z Researchers ask: Is China the sleeping g... Researchers ask: Is China the sleeping giant of biotech? PARIS (AFP) — China's biotech sector accounts for just a sliver of its pharmaceutical industry and operates under the cloud of a massive review of licenses issued under a regulator executed last year for accepting bribes. Even so, experts say, Chinese purveyors of genetically engineered drugs and vaccines -- targeting everything from cancer to Alzheimer's -- are growing at a frenzied pace and are likely to become major actors on the world stage. "There is no question that the sector is established," said Peter Singer of the McLaughlin-Rotman Centre for Global Health in Toronto who was lead researcher of a study published Monday in Nature Biotechnology. "What we found really surprising is that in an industry that's only 10 years old, China has innovative products on the market," he told AFP For their study, Singer and his colleagues selected 22 small- and medium-sized biotech firms from literally thousands operating in the health sector for close scrutiny. They looked for companies that were innovative, both scientifically and in business. The portrait that emerged is of a dynamic sector that has been growing 30 percent annually over the past decade, reaching a turnover of three billion dollars in the domestic market in 2005. Yet its activity is dominated by a few big stars and remains dogged by doubts as to its integrity. It is also a sector led in large measure by "sea turtles" ("hai gui") -- Chinese-born scientists with a decade or two of US or European lab experience under their belts who have come home to found Chinese companies, often with generous backing from the government. In a market of one billion potential patients, 15 biotech products for health are already on the market, with another 60 in the pipeline, Singer said. Exhibit A: Gendicine, the first gene therapy product approved after clinical trials anywhere in the world. A recombinant human adenovirus, Gendicine carries the p53 gene and is administered by injection directly into cancerous tumours in the head and neck, including nasopharyngeal carcinoma. More than 5,000 patients have received the treatment in combination with radiotherapy, including 400 foreign patients from outside China. The company became profitable shortly after the launch of the product, approved in 2005 by China's State Drug and Food Administration (SDFA). That, as it turns out, was not an unimpeachable recommendation. The SDFA's former director, Zheng Xiaoyu, was executed in July 2007 for accepting bribes in return for issuing drug approvals without proper review. As a result, a staggering 170,000 licenses granted by the SDFA, especially between 1999 and 2002, are currently under review. Another company, Shenzhen Beike Technologies, provides a treatment based on umbilical cord and bone marrow stem cells for Alzheimer's, autism, brain trauma, cerebral palsy and spinal cord injury, as well as a dozen other diseases and conditions. The medication is injected directly into the spinal cord of patients. "There is no need to do clinical trials for this kind of procedure in China," said the study's lead author, Sarah Frew, also a researcher at McLaughlin-Rotman. "The approach this company is taking is trying the thing on patients rather than doing scientific research," added Singer. The product has nonetheless been a commercial success, first with Chinese patients and more recently with international patients. When Frew visited the clinic a year ago, there were a dozen foreigners present. The company's website is filled with glowing testimonials on the effectiveness of the treatment, which costs tens of thousands of dollars. In most cases the therapies and vaccines developed in China are far less controversial. Indeed, more than 90 percent of products produced in the health biotech sector are biogenerics, with novel products accounting for 3-to-5 percent of the total. A more recent development are international joint ventures and investment. Shenzhen Chipscreen Biosciences, for example, has developed an anti-cancer drug in cooperation with Huya Bioscience, based in San Diego, California. Once the medication is on the market, the Chinese partner will hold the rights for China, while Huya can lay claim to the rest of the world. WuXi PharmaTech, which was listed on the New York Stock Exchange in the summer of 2007, is the first biotech service company in China with major foreign clients, including US pharmaceutical giant Merck and Britain's AstraZeneca. The fact that WuXi has attracted such companies "punctures a little bit the legend that there is no intellectual property in China," said Singer. Another myth that may soon fall by the wayside is that China can only reproduce what other have done already. "There is no longer a hegemony on the part of industrialised countries in global biotech innovation," Singer said. とりあえずの記事の投稿の仕方 tag:sekizui.info,2008:/news//2.11 2008-01-08T08:14:07Z 2008-01-08T08:46:57Z ここんところ、とんと治療法の研究のニュースを集めていなかったもので、最近どういう... ここんところ、とんと治療法の研究のニュースを集めていなかったもので、最近どういうニュース、情報があったのか、よく分からない状態です。 別に治療法の研究に期待薄になったわけでは全然なくて、ただ単に、ｲﾛｲﾛ忙しかった、気が向かなかった、などなど、そんなところです。 だけど、IPS細胞のニュースなどテレビでやるような有名ニュースは興味シンシンで、もちろん見てました。 山中教授・・・・ﾊﾟﾝﾊﾟﾝ(-人-;)　　ありがたい、お方です。(笑) 早くノーベル賞あげろよ！！ あと岡野教授ﾊﾟﾝﾊﾟﾝ(-人-;)のチームと2年後をめどにサルで試験もするとか！ こう考えると去年は年末にいいニュースがいっぱいあったな♪ えっと、とりあえず、過去1年ぐらいのニュースを遡って、良さそうなニュース、情報を探して、載せていきます！ なにか、ここに載ってないニュースで良い記事があったら教えてください。 　　情報求む！ヽ(´∀｀)9 ﾋﾞｼ!! 記事の投稿の仕方は、後から見やすいように、投稿日が記事の出た日になるように投稿日を指定して投稿します。 昨日、今日、当サイトを再開しだしたので、過去の日付けの投稿があっても、それは、過去に投稿したものではなく、今日、昨日、投稿したものです。 この方法で、当分、過去の記事を集めていきたいと思っております。 ■＿ヾ(・・*)カタカタ 難しい質問は(ヾﾉ･∀･｀)ﾑﾘﾑﾘ tag:sekizui.info,2008:/news//2.10 2008-01-08T06:57:05Z 2008-01-08T08:11:30Z 管理人はイチ脊髄損傷の患者です。 仕事も、イチ小売業者です。医学とは医療とかとは... 管理人はイチ脊髄損傷の患者です。 仕事も、イチ小売業者です。医学とは医療とかとは無縁の者です。 ネットで、脊髄損傷の治療法の研究に関係あるニュース記事や情報を集めるのが好きなイチ自営業者です。 ですので、 この病気にはどうやって対処すればいいか？ この治療法についてどう思うか？ この症状にはどうやって対処すればいいか？ などなど、医者じゃないと答えられないような質問は答えられませんので、ご勘弁を(;^_^A あと人生相談、これも ((乂ﾟдﾟ　)ﾑﾘｯﾀﾗｯﾑﾘ!!!(　ﾟдﾟ乂)) 治療法の研究関連のニュースや情報を集めるのが好きな、 いち患者です。 記事の著作権って一体・・ tag:sekizui.info,2008:/news//2.8 2008-01-08T06:26:05Z 2008-01-08T08:13:58Z 新聞記事の著作権て一体どうなってるんだろ？ 今後も、このサイトにネットで記事を見... 新聞記事の著作権て一体どうなってるんだろ？ 今後も、このサイトにネットで記事を見つけては貼り付けるつもりなんだけど。。 厳密に言えば、これって、著作権的に問題なんではないだろうか？ でも、以前にどこかで見たけど、配信元とかを書いておけば問題ないみたいなことが書いてあったような覚えがするけど。。。 でも第一、ブログとか見ると、海外でも日本でも結構な有名サイトがばんばん記事を貼り付けてあるし。。暗黙の了解なのかな。 ま、当サイトも面倒なことは嫌なので新聞社とかから注意が来たら即刻消しますけどね。配信元の方、どうか大目に見てやってください。 とは、言いつつ、ウチは自分が書いたのをコピーされたら ┣¨┣¨┣¨ε=ε=ｺﾄﾜﾙｯヽ(o'∀')ﾉ┌┛ｶﾞｯΣ(；ﾉ｀ω´)ﾉ だけど(笑)小さいです！